Page last updated: 2024-11-04

sulforaphane and Parkinsonian Disorders

sulforaphane has been researched along with Parkinsonian Disorders in 1 studies

sulforaphane: from Cardaria draba L.
sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.

Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.

Research Excerpts

ExcerptRelevanceReference
"However, the disease progression remains unaffected, because of continuous dopaminergic neuron loss."1.37Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism. ( Cuadrado, A; Fernández-Ruiz, J; Hesse, M; Innamorato, NG; Jazwa, A; Rojo, AI, 2011)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Jazwa, A1
Rojo, AI1
Innamorato, NG1
Hesse, M1
Fernández-Ruiz, J1
Cuadrado, A1

Other Studies

1 other study available for sulforaphane and Parkinsonian Disorders

ArticleYear
Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism.
    Antioxidants & redox signaling, 2011, Jun-15, Volume: 14, Issue:12

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anticarcinogenic Agents; Antioxidants; Basal

2011